Publications by authors named "L Gilissen"
Genetic association analysis and frequency of NUDT15*3 with thiopurine-induced myelosuppression in patients with inflammatory bowel disease in a large Dutch cohort.
Maarten J Deenen Anouk J van Noordenburg Joëlle Bouwens-Bijsterveld Maarten A van Dijk Janneke M Stapelbroek Lennard P L Gilissen
Pharmacogenomics J
November 2024
Article Synopsis
- Thiopurine drugs are crucial for managing inflammatory bowel disease (IBD), but they can cause side effects, particularly thiopurine-induced myelosuppression (TIM).
- A study in the Netherlands explored the frequency of the NUDT15*3 genetic polymorphism and its connection to TIM in IBD patients.
- Out of 988 patients, 1.3% had the NUDT15*3 variant; among those on thiopurines, 50% of carriers developed TIM compared to just 2.3% of non-carriers, indicating the importance of genetic testing before treatment.
Predicting mucosal inflammation in IBD patients using patient-reported symptom scores and a faecal calprotectin home test: protocol for a multicentre prospective validation study.
Laura Janssen Reinier Cornelis Anthonius van Linschoten Rachel Louise West Lennard P L Gilissen Mariëlle Romberg-Camps
BMJ Open
October 2024
Introduction: Crohn's disease and ulcerative colitis are chronic inflammatory bowel diseases (IBD) with a relapsing-remitting nature. With adequate non-invasive prediction of mucosal inflammation, endoscopies can be prevented and treatment optimised earlier for better disease control. We aim to validate and recalibrate commonly used patient-reported symptom scores combined with a faecal calprotectin (FC) home test as non-invasive diagnostic tool for remote monitoring of IBD, both in daily practice and in a strict trial setting.
View Article and Find Full Text PDFArticle Synopsis
- The study evaluated the effectiveness of a treat-to-target (T2T) approach using faecal calprotectin (FC) levels compared to symptom-based management for mild-to-moderate ulcerative colitis (UC).
- It was a randomized controlled trial involving 193 patients, where the interventional group utilized FC values for treatment adjustments, while the reference group relied solely on clinical symptoms.
- Results showed no significant difference in the primary endpoint, but the T2T approach had a higher rate of achieving composite endpoint goals, indicating it may offer better disease control in the long run.
Article Synopsis
- This study looked at how safe the medicine allopurinol is for pregnant women, especially those with a condition called inflammatory bowel disease (IBD).
- Researchers gathered data from 42 pregnancies where mothers took allopurinol and found some complications, like miscarriages and a baby born with a heart issue.
- Overall, the findings suggest that allopurinol might not significantly increase the risk of birth defects in babies born to mothers with IBD who took this medicine.